(+)-(1S,2S)-2-exo-bromonorbornane-1-carboxylic acid | 104113-38-4

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: (+)-(1S,2S)-2-exo-bromonorbornane-1-carboxylic acid
• 英文别名: (1S,2S,4R)-2-bromobicyclo[2.2.1]heptane-1-carboxylic acid
• CAS: 104113-38-4
• 化学式: C₈H₁₁BrO₂
• 分子量: 219.078
• InChiKey: YOBWYLCYNUIVKF-VMHSAVOQSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.88
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  exo-2-bromobicyclo<2.2.1>heptane-1-carboxylic acid 在 吡啶 、 硫酸 、 对甲苯磺酰氯 作用下， 反应 1.0h， 生成 (+)-(1S,2S)-2-exo-bromonorbornane-1-carboxylic acid
  参考文献：
  名称：

  （+）-2-外-溴降冰片烷-1-羧酸和（-）-1-碘-2-外-溴降冰片烷的绝对构型

  摘要：

  通过（HPLC）分离由该酸和（+）-（R）-苯基甘氨醇制得的非对映异构酰胺，可实现（±）-2-外-溴-降冰片烷-1-羧酸的拆分。通过X射线结构分析确定绝对构型并与cd光谱相关。

  DOI：

  10.1039/c39860000297

文献信息

• Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
  申请人：——

  公开号：US20020019411A1

  公开（公告）日：2002-02-14

  Dipeptidyl peptidase IV (DP 4) inhibiting compounds are provided having the formula 1 where x is 0 or 1 and y is 0 or 1 (provided that x=1 when y=0 and x=0 when y=1); n is 0 or 1; X is H or CN; and wherein R 1 , R 2 , R 3 and R 4 are as described herein. A method is also provided for treating diabetes and related diseases, especially Type II diabetes, and other diseases as set out herein, employing such DP 4 inhibitor or a combination of such DP 4 inhibitor and one or more of another antidiabetic agent such as metformin, glyburide, troglitazone, pioglitazone, rosiglitazone and/or insulin and/or one or more of a hypolipidemic agent and/or anti-obesity agent and/or other therapeutic agent.

  提供了具有公式1的抑制二肽基肽酶IV（DP 4）的化合物，其中x为0或1，y为0或1（前提是当y=0时，x=1，当y=1时，x=0）；n为0或1；X为H或CN；其中R1、R2、R3和R4如本文所述。还提供了一种治疗糖尿病和相关疾病，特别是II型糖尿病以及本文中列出的其他疾病的方法，使用这种DP 4抑制剂或这种DP 4抑制剂与另一种或多种抗糖尿病药物（如二甲双胍、格列本脲、曲格列酮、吡格列酮、罗格列酮和/或胰岛素）的组合，以及一种或多种降脂药物和/或抗肥胖药物和/或其他治疗药物。
• Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV, process for their preparation and their use
  申请人：Bristol-Myers Squibb Company

  公开号：EP1559710A2

  公开（公告）日：2005-08-03

  Dipeptidyl peptidase IV (DP 4) inhibiting compounds are provided having the formula (I) where x is 0 or 1 and y is 0 or 1 (provided that x = 1 when y = 0 and x = 0 when y = 1); n is 0 or 1; X is H; and wherein R1, R2, R3 and R4 are as described herein. A method is also provided for treating diabetes and related diseases, especially Type II diabetes, and other diseases as set out herein, employing such DP 4 inhibitor or a combination of such DP 4 inhibitor and one or more of another antidiabetic agent such as metformin, glyburide, troglitazone, pioglitazone, rosiglitazone and/or insulin and/or one or more of a hypolipidemic agent and/or anti-obesity and/or other therapeutic agent.

  提供了具有式（I）的二肽基肽酶 IV（DP 4）抑制化合物 其中 x 为 0 或 1，y 为 0 或 1（条件是当 y = 0 时 x = 1，当 y = 1 时 x = 0）；n 为 0 或 1；X 为 H；其中 R1、R2、R3 和 R4 如本文所述。还提供了一种治疗糖尿病和相关疾病，特别是II型糖尿病，以及本文所述的其他疾病的方法，该方法采用了这种DP 4抑制剂或这种DP 4抑制剂与另一种或多种抗糖尿病剂如二甲双胍、甘氟脲、曲格列酮、吡格列酮、罗格列酮和/或胰岛素和/或一种或多种降血脂剂和/或抗肥胖和/或其他治疗剂的组合。
• N-Protected amino hydroxy adamantane carboxylic acid and process for its preparation
  申请人：Bristol-Myers Squibb Company

  公开号：EP2272825A2

  公开（公告）日：2011-01-12

  Dipeptidyl peptidase IV (DP 4) inhibiting compounds are provided having the formula (I) where x is 0 or 1 and y is 0 or 1 (provided that x = 1 when y = 0 and x = 0 when y = 1); n is 0 or 1; X is H; and wherein R1, R2, R3 and R4 are as described herein. A method is also provided for treating diabetes and related diseases, especially Type II diabetes, and other diseases as set out herein, employing such DP 4 inhibitor or a combination of such DP 4 inhibitor and one or more of another antidiabetic agent such as metformin, glyburide, troglitazone, pioglitazone, rosiglitazone and/or insulin and/or one or more of a hypolipidemic agent and/or anti-obesity and/or other therapeutic agent.

  提供了具有式（I）的二肽基肽酶 IV（DP 4）抑制化合物 其中 x 为 0 或 1，y 为 0 或 1（条件是当 y = 0 时 x = 1，当 y = 1 时 x = 0）；n 为 0 或 1；X 为 H；其中 R1、R2、R3 和 R4 如本文所述。还提供了一种治疗糖尿病和相关疾病，特别是II型糖尿病，以及本文所述的其他疾病的方法，该方法采用了这种DP 4抑制剂或这种DP 4抑制剂与另一种或多种抗糖尿病剂如二甲双胍、甘氟脲、曲格列酮、吡格列酮、罗格列酮和/或胰岛素和/或一种或多种降血脂剂和/或抗肥胖和/或其他治疗剂的组合。
• Protected amino hydroxy adamantane carboxylic acid and process for its preparation
  申请人：AstraZeneca AB

  公开号：EP2272825B1

  公开（公告）日：2015-11-04
• CYCLOPROPYL-FUSED PYRROLIDINE-BASED INHIBITORS OF DIPEPTIDYL PEPTIDASE IV, PROCESSES FOR THEIR PREPARATION, AND THEIR USE
  申请人：Bristol-Myers Squibb Co.

  公开号：EP1261586A2

  公开（公告）日：2002-12-04